Neurocrine Biosciences, Inc. (nbix)
NBIX Earnings
Public earnings and growth snapshot for Neurocrine Biosciences, Inc.. Full earnings calendars, surprises, and multi-year history are available in Vest Terminal.
| Earnings growth (YoY) | 31.1% |
| Revenue growth (YoY) | 39.5% |
| Trailing P/E | 20.76 |
| Forward P/E | 11.65 |
| Last price | $139.49 |
| Market cap | $14.18B |
Start Free — open NBIX in Vest Terminal
Access live data, filings, ownership, and analysis for Neurocrine Biosciences, Inc..
Neurocrine Biosciences, Inc. FAQ
What does Neurocrine Biosciences, Inc. (NBIX) do?
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associate…
What is NBIX's P/E ratio?
Neurocrine Biosciences, Inc. has a trailing P/E of 20.76× based on publicly available market data.
Does NBIX pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is NBIX in?
Neurocrine Biosciences, Inc. is classified in Healthcare (Drug Manufacturers - Specialty & Generic) on NMS.
What is NBIX's market capitalization?
Approximate market cap: $14.18B.
What are the main risks for NBIX?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of NBIX?
Potential positives include revenue growth of 39.5% year-over-year, earnings growth of 31.1% year-over-year.
Where can I get analyst estimates for NBIX?
Public analyst price targets and consensus for Neurocrine Biosciences, Inc. are on the free /stocks/nbix/estimates page. Deeper estimate history and models are available in Vest Terminal.